(Yicai Global) June 12 -- Chinese drugmaker Tasly Pharmaceutical Group will acquire regional exclusive rights to develop and sell a medicine for secondary hyperparathyroidism, often caused by kidney failure.
Tasly paid Japanese EA Pharma for a license to produce the drug in China's mainland, as well as in Hong Kong and Macao, the Tianjin-based medical firm said in a statement, without disclosing the price of the deal. Clinical trials of the new drug are expected to be completed in Japan by this year.
The intravenous medicine can lower parathyroid hormone in a sustained manner, and reduce the usual side effects of such treatment. The medicine will help broaden the listed company’s product line in the overall chronic disease market, the statement said. The drugmarker also warned that there is a deal of uncertainty surrounding the treatment due to its developmental nature, with a long clinical trial cycle involving high risks.
Editor: Emmi Laine